Agah Shahram, Akbari Abolfazl, Talebi Atefeh, Masoudi Mohsen, Sarveazad Arash, Mirzaei Alireza, Nazmi Farinaz
a Colorectal Research Center , Iran University of Medical Sciences , Tehran , Iran.
b Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital , Iran University of Medical Sciences , Tehran , Iran.
Cancer Invest. 2017 Nov 26;35(10):625-632. doi: 10.1080/07357907.2017.1408814.
Cell-free circulating DNAs (cfcDNAs) have been recognized as promising biomarkers for a number of cancers. This study aimed to quantify the cfcDNA in colorectal cancer to assess its potential value as biomarker. Quantification of baseline cfcDNA was determined as the amount of free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in plasma, using quantitative real-time polymerase chain reaction (PCR). The calculated area under the curve (AUC) of receiver operating characteristic (ROC) for cfcDNA was 0.875 (95% CI, 0.811-0.94), which was indicative of a high discriminatory power (p < 0.001) and significant accuracy in distinguishing cancer patients from healthy individuals. The quantification of cfcDNA could be useful for clinical settings of CRC.
游离循环DNA（cfcDNA）已被公认为多种癌症的有前景的生物标志物。本研究旨在对结直肠癌中的cfcDNA进行定量，以评估其作为生物标志物的潜在价值。使用定量实时聚合酶链反应（PCR），将基线cfcDNA的定量确定为血浆中游离甘油醛-3-磷酸脱氢酶（GAPDH）的量。cfcDNA的受试者工作特征（ROC）曲线下面积（AUC）计算值为0.875（95%CI，0.811 - 0.94），这表明其具有高鉴别力（p < 0.001），且在区分癌症患者与健康个体方面具有显著准确性。cfcDNA的定量对于结直肠癌的临床应用可能是有用的。
